NCT01635465Unknown不适用
A Randomised Controlled Phase II Trial of Vinorelbine Plus Capecitabine Versus Docetaxel Plus Capecitabine in Anthracycline-pretreated Women With Metastatic Breast Cancer.
Tianjin Medical University Cancer Institute and Hospital1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2016年11月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- RECIST 1.1
研究概览
简要总结
Docetaxel plus Capecitabine in anthracycline-pretreated metastatic breast cancer is a recommended scheme in National Comprehensive Cancer Network (NCCN) guideline. Vinorelbine plus Capecitabine is also effective in Metastatic Breast Cancer (MBC) in some clinical study with small sample.
详细描述
A randomised controlled trial of vinorelbine plus capecitabine versus docetaxel plus capecitabine in anthracycline-pretreated women with metastatic breast cancer. The primary endpoints of the study is progression free survival (PFS). The secondary endpoints are overall response rate (ORR), overall survival (OS) and safety.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •female ≥ 18 years old ECOG 0-2
排除标准
- •brain metastasis
结局指标
主要结局
RECIST 1.1
时间窗: -7 days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Capecitabine in the Treatment of Breast Cancer With Low-hormone Receptor Expression After Neoadjuvant ChemotherapyBreast CancerNCT03821454Zhejiang Cancer Hospital50
Unknown
4 期
Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast CancerMetastatic Breast CancerNCT02207361Tianjin Medical University Cancer Institute and Hospital120
已完成
2 期
A Study to Evaluate Safety and Efficacy of Caelyx in Combination With Cyclophosphamide in the Treatment of Metastatic Breast Cancer (P02948)Breast NeoplasmNCT00779129Merck Sharp & Dohme LLC70
已完成
1 期
Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast CancerMetastatic Breast CancerNCT00645333University of Michigan Rogel Cancer Center30
终止
2 期
Nab-paclitaxel in Metastatic Breast Cancer Patients Failing Solvent Based Taxane (Tiffany)Metastatic Breast CancerNCT01416558German Breast Group66